Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1997-12-5
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0931-0509
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
12
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2047-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9351060-Aspirin,
pubmed-meshheading:9351060-Cardiovascular Diseases,
pubmed-meshheading:9351060-Goals,
pubmed-meshheading:9351060-Humans,
pubmed-meshheading:9351060-Hypertension,
pubmed-meshheading:9351060-Morbidity,
pubmed-meshheading:9351060-Prospective Studies,
pubmed-meshheading:9351060-Randomized Controlled Trials as Topic
|
pubmed:year |
1997
|
pubmed:articleTitle |
What have we learned from the HOT (Hypertension Optimal Treatment) study?
|
pubmed:publicationType |
Editorial
|